Correlation between morphology and EGFR mutations in lung adenocarcinomas

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.4K citations

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

Vincent A. Miller, Mark G. Kris, Neelam Shah et al. · Journal of Clinical Oncology · 2004 · 744 citations

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

Mark M. Moasser, Andrea Basso, Steven D. Averbuch et al. · PubMed · 2001 · 508 citations

Breast Oncology, Her2-driven Signaling, Tumor Biology +20

Micropapillary Component in Lung Adenocarcinoma

Mitual Amin, Pheroze Tamboli, Shakil H. Merchant et al. · The American Journal of Surgical Pathology · 2002 · 330 citations

Lung Carcinoma, Multiple Pulmonary Nodule, Micropapillary Carcinoma Component +10